Miglustat Patent Expiration
Miglustat was first introduced by Actelion Pharmaceuticals Us Inc
Miglustat Patents
Given below is the list of patents protecting Miglustat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opfolda | US12246062 | Recombinant human acid alpha-glucosidase | Sep 16, 2038 | Amicus Therap Us |
| Opfolda | US10857212 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | Aug 12, 2037 | Amicus Therap Us |
| Opfolda | US11278601 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | Dec 29, 2036 | Amicus Therap Us |
| Opfolda | US10208299 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US10961522 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US11753632 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | Sep 30, 2035 | Amicus Therap Us |
| Opfolda | US10512677 | High concentration alpha-glucosidase compositions for the treatment of pompe disease | Mar 07, 2033 | Amicus Therap Us |
| Opfolda | US11278599 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | Mar 07, 2033 | Amicus Therap Us |
| Zavesca | US5525616 | Method of inhibiting glycolipid synthesis |
Jun 11, 2013
(Expired) | Actelion |
| Zavesca | US5472969 | Method of inhibiting glycolipid synthesis |
May 13, 2013
(Expired) | Actelion |
Miglustat's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List